Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus heriz i
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus Heriz I is a specific strain of the Lacticaseibacillus rhamnosus bacterium, which is a type of probiotic. This particular strain was isolated from traditional yogurt in the Heriz region of Iran and has been registered in the NCBI GeneBank. It has been studied for its potential immunomodulatory effects, particularly as a supplementary treatment for patients undergoing chemotherapy. In a clinical trial involving women with breast cancer, *Lactobacillus rhamnosus* Heriz I was administered in combination with Beta Glucan. The study found that this combination may be useful as an immunomodulatory supplement, observing a decrease in serum levels of IL-4 and a non-significant increase in IL-12, suggesting a shift in the immune response. The trial also reported improvements in functional quality of life scores for patients receiving the supplement combination compared to placebo. It is administered orally in capsule form.
- Other names
- L. rhamnosus Heriz I
Beyond the preview
Go deeper on lactobacillus rhamnosus heriz i.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus heriz i.